...is under review in Brazil. Hypermarcas said it will receive between BRL30-BRL35 million ($17.9-$20.9 million). Hypermarcas...
...as Sensipar . Amgen markets romiplostim as Nplate . Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Hypermarcas...

...disclosed. Additionally, Amgen reacquired rights in Brazil to Vectibix panitumumab, Mimpara cinacalcet and romiplostim from Hypermarcas...
...hyperparathyroidism and hypercalcemia, respectively. Romiplostim is under review in Brazil for idiopathic thrombocytopenic purpura (ITP). Hypermarcas...